you We to us and them. market today. Thank Good a you've our chance a look closed afternoon quarter and thank after you. at first for the had this take afternoon, I results joining hope distributed
we paradigm developments discussion and quarter, technologies to positioned position stated our has company, for the company's advances which the take as The value diagnostics and cost in I the achieve of a progress get addressing well plan, about Before results today's talk goal. both the and this advance a marketplace, industry goal dynamics. reality a into to designed for financial I establishing minutes operational three-prong unlock initiatives compelling new the several against thought never important been of to fiscal and company modern our a includes few day would in sophisticated of and innovation, as better
which such signaling targeting at is development is cancers. modulation in a develops the enabling We shareholders, as continued its the various Therapeutics portfolio cancers various is broad designs and immune are implicated based subsidiary. therapeutic value indications crossroads disorders. enhance excited pathways today and Steatohepatitis, in Crohn's for company regulation specific to to part and as unlock The for disease, immune and the avenues value of Non-Alcoholic therapeutic company's business variety that considering of managing programs, mediated company a of actively range focus create to oral a our announce Enzo that to of on are platforms on treatments NASH,
recognize this or capital to requirements committed necessary consideration, point Enzo include remains While path licensing address the commercialization, fully of the would the The joint of Board venture, the strategic the it determination Therapeutics, that drive and given consider company to property. alternatives Directors spin-off, the to various validation alternatives. at intellectual therapeutic the opportunities of value, its made significant under subsidiary’s sale, for further a
investment diligently teams working on with as to they and finance the along legal forward our our on next bankers emerge. we this Our steps updating shareholders are will initiative, look and
In with report and growth, drive intellectual manage of We're our short our these medium-term build-off three-prong development, against operations, was platform substantial of profitable shared Enzo making pleased a strategy June, we objectives. each to legacy manufacturing, shareholders innovation, and our effectively designed progress property. more to and that
are we for testing, clinical for molecular as know and vertically declining central we manage We small serve continued we and of additional formalized with As pressure lower a manufacturer their reimbursement lab-to-lab in today, announced rate terms labs. relationships to needs three a to cost integrated earlier to community, provider have that under actively mid-sized which service relationships, negotiating a have desperately the capability marketplace. wherewithal and laboratory the businesses as
investment several disclose from our the We hope in and of working near-term. our value to are the gratified labs our businesses. update offering by able banker this diagnostics are in we reaction Also in strategic partners discussions Lazard We the be see an for the engaged with these who model. new in to with creation
we business, of new a testing. the model talking In labs diagnostic and to are be clear, about
We continue to costs, steps take in while high growth operational areas. to investing also reduce
and XX% diagnostic been menu products We York have for demonstrated have of we number costs. we and a goal achieve validated and approval tests, have platforms reduction a New to significantly, in granted of XX% can our of that multiple these costs in primary broad a diverse reduce
of tests. development has our Women's Health XXX,XXX test in in high This the these for as as well in independently-developed better in resulting fully run is Panel been Our over samples, Molecular returns Diagnostics utilization a on products generating industry. instituted lab, others It for and meaningful is our lab. now our is margins these
which of achieve affect reimbursements, a in careful while There is operating difficult and in reducing a of continued costs science profitability. us, in balance our milestones, innovation and a great front will opportunity it require of these to environment in declines investment but manufacturing,
implementing in new personnel, in in same said the quarter, expenses to made earnings a we we've while about in our of initiatives investments time the billing new payers, systems, up opened series onboarded year. coming we've million labs and release, service As in $XX centers, our routine at we patient by new the first reduce the new
focusing another hospital also team, an appointment in investment executive On industry a the announced investment Management, the today consulting and our emerging work, to Arete today. Vice day-to-day management I as initiatives banking. of joins the he was now experienced perhaps of practices. exciting media tenure an more is Prior the that Group, firm the electronic health company position and subsequently President and broaden laboratories, DBC and Financial at of Mr. management, services ELLKAY, Bench advisory Chief Mr. investment President and to long in Bench front the of my role and as banker we Wealth technology Chief at be oversight, at a will from as Enzo. Lazard, served banking diagnostics operations, time Arnhold David Mr. President Research as importantly, growth company the Director, public industry, healthcare he medical Financial laboratory systems, companies, was front ELLKAY, day-to-day with information David and ambulatory over and and company Bench more advisory telecommunications and career his career Officer He our Bench diagnostic financial will covering of on healthcare technology providers, the payors, us depth Bleichroeder. take industries. his division will of my Chief in Officer. was in the technology to on and with this in retain where able of working Officer spend started the S. an Financial as record at
were into resolution, charges this hopeful $XXX,XXX by several our dispute we in expenses quarter. contest it another the financials, quarter's by related ongoing was provider worth spent Before we noting in In the get non-routine the for where favorable $XXX,XXX in pending of to a that are cash was the company. and withheld legal is proxy an a impacted results quarter,
financials like to year-over-year compared $XX.X the million of operating quarter and to turn $XX.X million, to revenues would to the amounted prior review the X% a quarter. is to now decline, gain, I increased for as Total greater compared $X.X reflecting this from revenues to volume the products yet diagnostic year, Product for research products. million of clinical X%. increased and sales accession a year-over-year was X% segment volume U.S. in million, up $X.X
reimbursements, Clinical revenues lower million reflects $XX.X to service requirements. $XX.X reimbursement rates company-related compared and testing of procedural in insurance the lab to changes million and This amounted ago. to million, genetics a reduced decrease $X.X decline due medical with year
Enzo is a fiscal a by to $X.X quarter compared million, and dispute reimbursements $X.X of first fiscal expenses Legal prior the payor charge million XXXX a third-party that with related year including related to $XXX,XXX amounted over contesting. to
cost $X.X slightly the new This expenditures operating the LDTs. $X.X on, factors. expenses. to from million million assays, the costs in million are that approximately previously-cited Total to R&D $X.X investments unusual were including revenues Overall, up I increased up is of $XXX,XXX. X.X%, and increased or XX%, commented reflecting due
increased $X.X flat volume was services, respectively versus ago. and and largely by to due reductions. to testing product margin million, of Clinical XX%, revenues $XXX,XXX million The higher remained higher of that XX% Product lower compared service volume. year respectively, a XX%, was XX% cost XX% At margins to about consolidated of year were a ago. revenues and clinical XX% $XX approximately at cost margin a offset with cost by
to loss $X.X primarily The services a reflecting product $X.XX compared reduced loss expenses. earlier. of or operating doubled is net $X.XX to income net GAAP loss revenues share million higher operating $X.X year $XXX,XXX loss from in or share, million from ago $X year of the million. segment The million, This totaled and $X.X amounted clinical a a operating $XXX,XXX. R&D The up per to
expenses calculation, non-GAAP approximately per Adjusted during loss year year's EBITDA last share, a million, a the a a negative of for to quarter per was to $X.X net EBITDA million. there $X.X negative 'XX compared totaling no share EBITDA, expenses. which $X.X amounted first ago. unusual $X.XX unusual loss $X.X fiscal million, of a million non-GAAP XXXX equaled Adjusted were
was the standards as the $X.X which current in XXXX, resulted accounting million lease changes October period, quarter operating new of of other adoption finally, for in assets and totaled in million. XX, in liabilities, million. working After $X.X used liabilities leases, of the And current of $XX.X capital cash and recognition operations the operating for
that On take be would to happy questions. I note,
